Filing Details
- Accession Number:
- 0001193125-24-032553
- Form Type:
- 13D Filing
- Publication Date:
- 2024-02-11 19:00:00
- Filed By:
- Pivotal Bioventure Partners Fund I, L.p.
- Company:
- Rallybio Corp
- Filing Date:
- 2024-02-12
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Nan Fung Group Holdings Limited | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| NF Investment Holdings Limited | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Pivotal bioVenture Partners Fund I | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Pivotal bioVenture Partners Fund I G.P. | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Pivotal bioVenture Partners Fund I U.G.P. Ltd | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Pivotal Partners Ltd | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Pivotal Life Sciences Holdings Limited | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
| Nan Fung Life Sciences Holdings Limited | 0 | 2,404,644 | 0 | 2,404,644 | 2,404,644 | 6.4% |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment 1)*
Rallybio Corporation
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
75120L 100
(CUSIP Number)
Robert Hopfner
Pivotal bioVenture Partners Fund I U.G.P. Ltd
501 2nd Street, Suite 200
San Francisco, CA 94107
(415) 697-1002
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February 12, 2024
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Nan Fung Group Holdings Limited | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
British Virgin Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
2
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
NF Investment Holdings Limited | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
British Virgin Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
3
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Pivotal bioVenture Partners Fund I, L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
WC | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
PN | |||||
4
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Pivotal bioVenture Partners Fund I G.P., L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
PN | |||||
5
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Pivotal bioVenture Partners Fund I U.G.P. Ltd. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
6
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Pivotal Partners Ltd | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
7
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Pivotal Life Sciences Holdings Limited | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
8
CUSIP No. 75120L 100
| 1. | Names of Reporting Persons.
Nan Fung Life Sciences Holdings Limited | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
British Virgin Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,404,644 | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,404,644 | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,404,644 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.4% | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
9
Item 2. Identity and Background
Item 2(a) and 2(f) are hereby amended and restated as follows:
| (a) | This Schedule 13D is being filed by each of the following persons (each, a Reporting Person): |
| (i) | Nan Fung Group Holdings Limited (NFGHL) |
| (ii) | NF Investment Holdings Limited (NFIHL) |
| (iii) | Nan Fung Life Sciences Holdings Limited (Nan Fung Life Sciences) |
| (iv) | Pivotal bioVenture Partners Fund I, L.P. (Pivotal) |
| (v) | Pivotal bioVenture Partners Fund I G.P., L.P. (Pivotal GP) |
| (vi) | Pivotal bioVenture Partners Fund I U.G.P. Ltd. (the Ultimate General Partner) |
| (vii) | Pivotal Partners Ltd (Pivotal Partners) |
| (viii) | Pivotal Life Sciences Holdings Limited (Pivotal Life Sciences, and together with Pivotal, Pivotal GP, Ultimate General Partner, and Pivotal Partners, the Pivotal Entities) |
Pivotal GP is the general partner of Pivotal, and Ultimate General Partner is the general partner of Pivotal GP. Ultimate General Partner is wholly-owned by Pivotal Partners. Pivotal Partners is wholly-owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly-owned by NFIHL, which is wholly owned by NFGHL. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached to the initial Schedule 13D as Exhibit 1.
| (f) | Pivotal is a Cayman Islands exempted limited partnership. Pivotal GP is a Cayman Islands exempted limited partnership. Ultimate General Partner is a Cayman Islands exempted company. Pivotal Partners is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL and NFGHL are incorporated in the British Virgin Islands. Mr. Kam Chung Leung, Mr. Pui Kuen Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are citizens of the Hong Kong Special Administrative Region of the Peoples Republic of China. Ms. Heqing Huang is a citizen of the Peoples Republic of China. Mr. Frank Kai Shui Seto is a citizen of Canada. Mr. Vincent Sai Sing Cheung and Ms. Vanessa Tih Lin Cheung are citizens of the United Kingdom. |
10
Item 5. Interest in Securities of the Issuer
Item 5(a) and 5(c) are hereby amended and restated as follows:
| (a) | The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 37,793,705 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2023. |
| (c) | None of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days. |
11
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 12, 2024
| NAN FUNG GROUP HOLDINGS LIMITED | ||
| By: | /s/ Tang Chun Wai Nelson | |
| Name: | Tang Chun Wai Nelson | |
| Title: | Director | |
| NF INVESTMENT HOLDINGS LIMITED | ||
| By: | /s/ Tang Chun Wai Nelson | |
| Name: | Tang Chun Wai Nelson | |
| Title: | Director | |
| NAN FUNG LIFE SCIENCES HOLDINGS LIMITED | ||
| By: | /s/ Sun Xintong | |
| Name: | Sun Xintong | |
| Title: | Director | |
| PIVOTAL BIOVENTURE PARTNERS FUND I, L.P. | ||||||
| By: | PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P. | |||||
| Its General Partner, | ||||||
| By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD | ||||||
| Its General Partner, | ||||||
| By: | /s/ Robert Hopfner | |||||
| Name: | Robert Hopfner | |||||
| Title: | Authorized Signatory | |||||
| PIVOTAL BIOVENTURE PARNTERS FUND I G.P., L.P. | ||||||
| By: | PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD | |||||
| Its General Partner, | ||||||
| By: | /s/ Robert Hopfner | |||||
| Name: | Robert Hopfner | |||||
| Title: | Authorized Signatory | |||||
12
| PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD | ||
| By: | /s/ Robert Hopfner | |
| Name: | Robert Hopfner | |
| Title: | Authorized Signatory | |
| PIVOTAL PARTNERS LTD | ||
| By: | /s/ Sun Xintong | |
| Name: | Sun Xintong | |
| Title: | Director | |
| PIVOTAL LIFE SCIENCES HOLDINGS LIMITED | ||
| By: | /s/ Sun Xintong | |
| Name: | Sun Xintong | |
| Title: | Director | |
13